News and Research Feed

Poor Dental Hygiene Linked to Brain Tissue Degeneration

DentalCareThe strongest evidence to date that poor dental hygiene is linked to brain degeneration has emerged from a recent study at the University of Florida Dental College. While cardiologists have long known that the bacteria that causes gingivitis (gum disease) may enter the blood stream adding to  heart issues, there had been fewer studies to link Alzheimer’s or other dementia to oral health.

Read more on HealthCentral and oral hygiene and brain health:

Purchase Minding Our Elders: Caregivers Share Their Personal Stories – paperback or ebook

“I hold onto your book as a life preserver and am reading it slowly on purpose...I don't want it to end.”  Craig William Dayton, Film Composer

Global Alzheimer’s Study Now Enrolling


Younger Onset Alzheimer’s Symptoms Surprisingly Different

Fog6When we think of Alzheimer’s symptoms we think of memory loss, yet this is not necessarily the case with younger onset Alzheimer's. Younger onset Alzheimer’s may present symptoms such as poor judgement and skewed thinking patterns before memory loss becomes evident. Researchers at University College London (UCL) studied 7,815 people who have been diagnosed with Alzheimer's. The point of the study was to determine if symptoms differed according to age of onset.

Read more on HealthCentral about differences in dementia onset symptoms when people are younger:

Purchase Minding Our Elders: Caregivers Share Their Personal Stories – paperback or ebook

“I hold onto your book as a life preserver and am reading it slowly on purpose...I don't want it to end.”  Craig William Dayton, Film Composer

Global Alzheimer’s Study Now Enrolling


Interview with Alzheimer's Association Stresses Economic Devastation Dementia Can Bring to Families

HandsSpouseA recent survey by the Alzheimer’s Association revealed that over half of our Alzheimer’s caregivers are cutting back on everyday necessities to cover the cost of Alzheimer’s care. To gain further insight into the findings of the survey, I interviewed Beth Kallmyer, Vice President of Constituent Services for the Alzheimer’s Association, along with Paul Hornback who attended the enormously successful conference in Washington, D.C. held by Alzheimer’s advocates to draw attention to the need for significantly more funding for Alzheimer's research.

Read more on HealthCentral about the new Alzheimer's Association survey on financial issues:

Purchase Minding Our Elders: Caregivers Share Their Personal Stories – paperback or ebook

“I hold onto your book as a life preserver and am reading it slowly on purpose...I don't want it to end.”  Craig William Dayton, Film Composer

Global Alzheimer’s Study Now Enrolling


Alzheimer’s Rate Declining as Heart Related Disease Better Managed

HeartHealthWe are, for good reason, repeatedly reminded of the horrifying statistics related to the development of Alzheimer’s disease. The number of people over the age of 65 is exploding and most dementia symptoms develop as a person ages. This is fact. In no way does this article intend to distract from the need to cure all types of dementia. However, there is one thing to celebrate. Alzheimer’s rates seem to be declining. 

Read more on HealthCentral about how, even though the fight needs to keep gaining momentum, the rate of AD is declining:

Purchase Minding Our Elders: Caregivers Share Their Personal Stories – paperback or ebook

“I hold onto your book as a life preserver and am reading it slowly on purpose...I don't want it to end.”  Craig William Dayton, Film Composer

Global Alzheimer’s Study Now Enrolling


Where Should Alzheimer's Funding Go: Cure or Care?

ResearcherWhen you hear the next plea for increased Alzheimer’s funding – and you’ll hear a lot of it during the upcoming Alzheimer’s Awareness months, both global and national – your first thought will likely be that the money should go into to find a cure. However, people who already have the disease, as well as those who care for them, may disagree. A recent survey showed that these people feel that more financial resources should be dedicated to helping them live life with some quality. Funding research is fine, but that will only help people years in the future. They need help now.  

 Read more on HealthCentral about where the money for Alzheimer's should go:

Support a caregiver or jump start discussion in support groups with real stories - for bulk orders of Minding Our Elders e-mail Carol

Global Alzheimer’s Study Now Enrolling 


Brain Games: Do They Offer Brain Protection or Simply Entertainment?

BraingamesDo brain games make a difference in staving off brain diseases such as Alzheimer’s or are they just harmless fun? While studies have been all over the map on this issue during the last few years, lately they indicate that at least formal brain training may help, which indicates to me that well designed informal brain training would have at least some validity. The National Institute on Aging (NIA) has this to say:

Read more on HealthCentral about brain games and their contribution to cognitive health:

Support a caregiver or jump start discussion in support groups with real stories - for bulk orders of Minding Our Elders e-mail Carol

Global Alzheimer’s Study Now Enrolling


Depression: How Big of a Risk Factor for Alzheimer’s Is It?

Brain9It seems that there’s always something new popping up in a headline stating that this condition or that disease increases our risk of developing Alzheimer’s disease. While the constant barrage of negative information can be frustrating, it’s simply a byproduct of the intense research being done to discover the cause or causes of Alzheimer’s. That’s all good. For people with depression, however, seeing their illness on lists for traits that make them more likely to develop AD is worrisome. How seriously should people with depression take this information about which they can do little?

Read more on HealthCentral about depression and Alzheimer's:

Purchase Minding Our Elders: Caregivers Share Their Personal Stories – paperback or ebook

“I hold onto your book as a life preserver and am reading it slowly on purpose...I don't want it to end.”  Craig William Dayton, Film Composer

Global Alzheimer’s Study Now Enrolling


Surprising Changes that May Indicate Dementia

BrainWhen the average person thinks of dementia, generally Alzheimer’s disease comes to mind, and when people think of Alzheimer’s they think of memory loss. Both of these conclusions are understandable since Alzheimer’s is the most common form of dementia and memory issues are often the first symptom of that disease. Surprising then, to many people, is the fact that there may be more subtle indicators of potential Alzheimer’s disease or other types of dementia than memory lapses. If we feel that dementia may be in our future or that of our loved one, what other indications of cognitive change should we watch for?

Read more on HealthCentral about subtle signs of potential dementia:

Purchase Minding Our Elders: Caregivers Share Their Personal Stories – paperback or ebook

“I hold onto your book as a life preserver and am reading it slowly on purpose...I don't want it to end.”  Craig William Dayton, Film Composer

Global Alzheimer’s Study Now Enrolling


What’s Developing in Alzheimer’s Disease Treatment

 By Lawrence Friedhoff, MD, PhD


Lawrence_FriedhoffMy work in Alzheimer’s disease therapeutics began about 20 years ago. After completing my medical training, I was interested to explore another side of medicine—how new drugs are developed.

Attitudes toward dementia have changed drastically over the past two decades. Back then, the term Alzheimer’s disease wasn’t widely used, nor was Alzheimer's disease seen as a credible illness. Instead, people referred to the symptoms of Alzheimer’s disease as "senile dementia,” an inevitable consequence of aging that was considered untreatable.

In the early 90’s, I began working for a mid-size pharmaceutical company, and was placed in charge of finding promising new drugs to bring to market. In looking through many drug candidates and speaking with the scientists who had invented them, I came across a molecule, “E2020,” that I suspected would be an effective treatment for Alzheimer’s disease. I was able to obtain some development budget for E2020, and worked with a small team to get the molecule worldwide drug approval. About 5 years later, that drug became available to patients as Aricept (donepezil), which was then, and is still, the most widely used Alzheimer’s disease treatment.

Scientific and public attitudes about Alzheimer's disease changed with the approval of Aricept and subsequent medications: doctors became more educated about the disease and its diagnosis, and patients and their caregivers became more optimistic about the development of even better treatments.

The medical and scientific communities want to answer that call. Recently, there has been a push to explore medicines targeting a particular protein, beta amyloid, which tends to accumulate in the brain as we age, and is associated with dementia. The hope that these beta amyloid-targeted products could cure Alzheimer's disease meant an enormous amount of time and money was put into their development. Unfortunately, thus far, these investigational drugs have not yet shown any convincing benefit to patients with Alzheimer’s disease.

Although scientists are still pursuing new beta amyloid treatments, I believe the scientific community is turning its attention back to neurotransmitter-targeted drugs, which, like Aricept, act on essential chemicals within the brain in order to augment the brain’s normal functions. I’m currently leading the development of one such drug, called RVT-101, which has strong evidence of benefit to mild-to-moderate Alzheimer’s patients’ cognition and ability to perform daily living activities.

RVT-101 appears to be very well tolerated and is an oral, once-daily pill, so it’s easy for patients to take. Based on the results obtained to date, we believe RVT-101 has a good chance of becoming a widely-used drug for treatment of Alzheimer’s disease and other dementias. We are currently enrolling patients in a Phase III clinical trial of RVT-101, and we think it will be the final trial needed in order to get FDA approval and make the drug available to all patients. Until then, all patients who enroll in and complete our large clinical trial will have the opportunity to receive RVT-101 for up to one full year.

It's important to understand that clinical trials are a fundamental part of getting new treatments to patients, and are especially important for Alzheimer's disease drugs. Tests of Alzheimer's disease treatments in animals have not been predictive of the results in human patients except in a few rare cases. Furthermore, clinical trials can provide benefit to both the patient and future generations: they provide patients an opportunity to get a new drug earlier than would otherwise be possible, and participants may contribute to the advancement of drugs that help other patients. As Alzheimer’s disease occurs more frequently in women than in men, women’s participation in clinical research is particularly important.

However, patients should remember that there is no guarantee that the investigational drug in a clinical trial will ultimately prove to be beneficial— and all drugs have side effects. If clinical trials interest you or a loved one, make sure to discuss participation with your doctor and the staff running the clinical trial in order to determine which clinical trial, if any, is right.

BIO:

Dr. Friedhoff's career in pharmaceutical R&D has spanned more than three decades. During this time he has led and managed teams that developed and obtained approval for six new drugs, including Aricept® (donepezil), the most widely used drug for the treatment of Alzheimer's disease. Dr. Friedhoff is the Chief Development Officer at Axovant Sciences, Inc., a biopharmaceutical company focused on dementia solutions. He is the author of "New Drugs: An Insider's Guide to the FDA Approval Process for Scientists, Investors, and Patients" and has authored and co-authored numerous articles for peer-reviewed publications. He holds an MD from New York University, a PhD in Chemistry from Columbia University, and is a Fellow of the American College of Physicians.

The MINDSET Study for Mild-to-Moderate Alzheimer’s Is Open for Enrollment! 

As a participant in the MINDSET study, Alzheimer’s patients and their caregivers can have access to study-related medical care from specialized teams in this field.  Participants can continue to see their regular doctor(s) while participating in this study, and medical insurance is not required to participate. 

Interested patients and caregivers are invited to visit www.AlzheimersGlobalStudy.com to see if they may pre-qualify.


3 Triggers for Alcohol Abuse in Elderly

Caregiver6Alcohol abuse can occur at any age, but in the past most doctors looked for the signs in younger people. There’s also a bias in society at large, including some doctors, that people who abuse alcohol will be of a certain type. It can be hard for a doctor to look at a sweet, grandmotherly woman and think that perhaps the “occasional” glass of wine she admits to drinking may actually be a good portion of a bottle on nightly basis. 

Read more on HealthCentral about alcohol and seniors:

Global Alzheimer’s Study Now Enrolling

Purchase Minding Our Elders: Caregivers Share Their Personal Stories – paperback or ebook

“I hold onto your book as a life preserver and am reading it slowly on purpose...I don't want it to end.”  Craig William Dayton, Film Composer